Has Golshan Fahimi, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,571 in general payments to Golshan Fahimi, MD across 38 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Golshan Fahimi, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Golshan Fahimi, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Golshan Fahimi, MD

Clinical Neurophysiology · Mission Viejo, CANPI 1376066548

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 38 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 14.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,028, more than ten times the $132 reported in 2022.

$2,571in general payments, 2019–2025

Across 38 payments — averaging $67.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Amgen$374
AbbVie$370
Lilly USA, LLC$257
TG Therapeutics, Inc.$243
Teva Pharmaceuticals USA, Inc.$227
Neurocrine Biosciences, Inc.$191
plus $910 from 11 others

What the payments were for

Food & beverage$2,571100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Amgen	3	$374
AbbVie	13	$370
Lilly USA, LLC	3	$257
TG Therapeutics, Inc.	2	$243
Teva Pharmaceuticals USA, Inc.	2	$227
Neurocrine Biosciences, Inc.	2	$191
Pfizer	2	$149
Nestle Healthcare Nutrition Inc.	1	$125
CSL Behring	1	$125
Avadel CNS Pharmaceuticals, LLC	1	$125
AstraZeneca	1	$122
Amneal Pharmaceuticals LLC	1	$119
Johnson & Johnson	2	$54
Averitas Pharma Inc.	1	$35
Biohaven Pharmaceutical Holding Company Ltd.	1	$22
Novo Nordisk	1	$21
Eisai Inc.	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

QULIPTA$250
INGREZZA$155
BRIUMVI$143
ZEPBOUND$125
UPLIZNA$125
ZAVZPRET$125
VOWST$125
LUMRYZ$125
Hizentra$125
Austedo XR$121
CREXONT$119
KISUNLA$112
AJOVY$106

How this compares

$2,571 in reported general payments places this provider in the 65th percentile of 49 clinical neurophysiology providers in California.

See all clinical neurophysiology providers in California →

Medicare billing

Part B allowed, 2024

$17,959

Medicare patients

Services billed

135

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Carbidopa-LevodopaCarbidopa/Levodopa	41	$1,976
Memantine Hcl	82	$1,829
Donepezil Hcl	123	$1,283
Gabapentin	96	$1,161
RivastigmineRivastigmine Tartrate	30	$878
Pregabalin	31	$553
Levetiracetam	16	$476
Primidone	20	$306
Phenobarbital	12	$249
Ondansetron OdtOndansetron	11	$152
Quetiapine Fumarate	23	$116
Propranolol Hcl	11	$95
Sumatriptan Succinate	13	$85

Paid to pharmacies, not to this prescriber.

Other clinical neurophysiology in Mission Viejo

Said BeydounLos Angeles$985K
Christopher LockStanford$159K
Srikanth MuppidiStanford$150K
Mitchell MiglisStanford$51K
Michael AminoffSan Francisco$41K
Safwan JaradehStanford$34K
Sadiq AltamimiPomona$30K
Margaret FerrisStanford$18K
Kathleen PostonStanford$18K
Alexander GevorgyanGlendale$14K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →